Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 13/20 | 0.43 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312621 | 0.96 | BRAF (0.44) | SLC2A1BRAFLCKMAPK14RAF1 | |
| SCHEMBL4719952 | 0.96 | BRAF (0.44) | SLC2A1BRAFLCKMAPK14RAF1 | |
| SCHEMBL4717609 | 0.89 | BRAF (0.41) | SLC2A1BRAFLCKMAPK14RAF1 | |
| SCHEMBL4716379 | 0.86 | SLC2A1 (0.55) | SLC2A1BRAFRAF1KDRFLT3 | |
| SCHEMBL4718430 | 0.85 | LCK (0.41) | BRAFLCKRAF1KDRFLT3 | |
| SCHEMBL4716479 | 0.82 | BRAF (0.54) | SLC2A1BRAFRAF1KDRFLT3 | |
| SCHEMBL4718677 | 0.80 | BRAF (0.51) | SLC2A1BRAFRAF1KDRFLT3 | |
| SCHEMBL4717251 | 0.80 | LCK (0.46) | BRAFLCKRAF1KDR | |
| SCHEMBL4715020 | 0.80 | GRM5 (0.39) | BRAFLCKMAPK14RAF1FLT3 | |
| SCHEMBL4716501 | 0.79 | BRAF (0.52) | SLC2A1BRAFRAF1KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | SLC2A1 2090/4885BRAF 2001/4885LCK 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.